Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma,
is clinically heterogeneous: 40% of patients respond well to current therapy and have …
is clinically heterogeneous: 40% of patients respond well to current therapy and have …
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
…, J Powell, D Botstein, JC Byrd, MR Grever… - The Journal of …, 2001 - rupress.org
The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy
of mature B cells with a characteristic clinical presentation but a variable clinical course. …
of mature B cells with a characteristic clinical presentation but a variable clinical course. …
The National Cancer Institute: cancer drug discovery and development program.
MR Grever, SA Schepartz, BA Chabner - Seminars in oncology, 1992 - europepmc.org
The discovery and development of novel therapeutic products for the treatment of malignancy
is vitally important to those physicians responsible for the management of cancer patients. …
is vitally important to those physicians responsible for the management of cancer patients. …
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A …
…, DR Head, J Weick, MR Grever… - Blood, The Journal …, 1999 - ashpublications.org
Therapeutic resistance is a major obstacle in the treatment of acute myeloid leukemia (AML).
Such resistance has been associated with rapid drug efflux mediated by the multidrug …
Such resistance has been associated with rapid drug efflux mediated by the multidrug …
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
JG Supko, RL Hickman, MR Grever… - Cancer chemotherapy and …, 1995 - Springer
The plasma pharmacokinetics of the antitumor antibiotic geldanamycin (GM; NSC 122750),
a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. …
a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. …
[PDF][PDF] Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and …
…, M Pearson, JK Waselenko, G Ling, MR Grever… - Journal of Clinical …, 2001 - Citeseer
Purpose: Rituximab has been reported to have little activity in small lymphocytic lymphoma (SLL)/chronic
lymphocytic leukemia (CLL) and to be associated with significant infusion-…
lymphocytic leukemia (CLL) and to be associated with significant infusion-…
Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia
…, LA Andritsos, F Awan, KA Blum, MR Grever… - JAMA …, 2015 - jamanetwork.com
Importance The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with
chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and …
chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and …
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
…, CD Bloomfield, MR Grever… - Proceedings of the …, 2010 - National Acad Sciences
A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60
years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or …
years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or …
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup …
IW Flinn, DS Neuberg, MR Grever… - Journal of Clinical …, 2007 - ascopubs.org
Purpose The combination of fludarabine and cyclophosphamide is an effective regimen for
patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by …
patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by …
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
…, T Lin, ML Hackbarth, JH Proffitt, D Lucas, MR Grever… - Blood, 2004 - ashpublications.org
The presence of p53 mutation or deletion predicts for poor response to conventional therapy
in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti…
in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti…